CMA Defends £100M Fine Over Advanz Thyroid Drug Pricing
The U.K.'s competition watchdog told a tribunal Wednesday that the prices charged by pharmaceutical company Advanz for its thyroid tablets were excessive and unfair as it began its defense of a...To view the full article, register now.
Already a subscriber? Click here to view full article